EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, INKT: Mink Therapeutics Inc

24 Oct 25 15:59
LAST:

14.86

CHANGE:
 0.82		OPEN:
14.40		HIGH:
15.25		ASK:
1.65		VOLUME:
28.9K
CHG(%):
5.76		PREV:
14.16		LOW:
14.01		BID:
1.64		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 2514.4015.2514.0114.9830.4K
23 Oct 2514.0514.5114.0514.169.6K
22 Oct 2514.8714.9714.0014.0515.9K
21 Oct 2514.5815.3514.3514.8729.6K
20 Oct 2514.2314.8414.1814.7729.2K
17 Oct 2514.1014.3113.8714.008.0K
16 Oct 2514.7615.0014.4014.4422.8K
15 Oct 2514.1514.9013.8114.7829.8K
14 Oct 2514.0314.2713.9214.1559.1K
13 Oct 2514.0514.4913.9514.0917.9K

COMPANY PROFILE

Name:Mink Therapeutics Inc
About:MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Sector:Healthcare
Industry:Biotechnology
Address:149 Fifth Avenue, New York, NY, United States, 10010
Website:https://minktherapeutics.com
CUSIP:603693102
CIK:0001840229
ISIN:US6036931029
FIGI:BBG012J84VS3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:14.572.0%
MA10:14.433.0%
MA20:14.522.4%
MA50:14.651.5%
MA100:14.214.6%
MA200:10.8537.0%
STO9:72.22
STO14:72.22
RSI14:48.00
MTM14:0.08
ROC14:0.01 
ATR:0.80 
Week High:15.353.3%
Week Low:13.877.1%
Month High:16.007.7%
Month Low:13.5337.0%
Year High:76.00411.4%
Year Low:0.463,108.1%
Volatility:35.34 

RECENT SPLITS

Date Ratio
28 Jan 20251-10